- Home
- CIEN vs NBIX Comparison
CIEN vs NBIX Comparison
Compare CIEN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIEN | NBIX |
|---|---|---|
| Founded | 1992 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 14.4B |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CIEN | NBIX |
|---|---|---|
| Price | $200.42 | $155.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $152.36 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 3.5M | 969.9K |
| Earning Date | 12-11-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.32 | ★ 12.44 |
| EPS | 0.98 | ★ 4.19 |
| Revenue | ★ $4,541,635,000.00 | $2,682,700,000.00 |
| Revenue This Year | $19.58 | $23.76 |
| Revenue Next Year | $16.89 | $18.01 |
| P/E Ratio | $205.91 | ★ $37.10 |
| Revenue Growth | 12.97 | ★ 19.61 |
| 52 Week Low | $49.21 | $84.23 |
| 52 Week High | $214.17 | $157.67 |
Technical Indicators
Market Signals| Indicator | CIEN | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 64.81 |
| Support Level | $186.39 | $150.26 |
| Resistance Level | $209.19 | $154.35 |
| Average True Range (ATR) | 10.53 | 4.16 |
| MACD | -0.80 | 1.07 |
| Stochastic Oscillator | 79.72 | 93.25 |
Price Performance
Historical ComparisonAbout CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.